Back to research

Research paper

Chromatinopathies: insight in clinical aspects and underlying epigenetic changes (review)

Review of ~154 epigenes now linked to Mendelian chromatinopathies, many with distinctive blood methylation episignatures. Signatures may overlap across functional complexes (KDM6A/KMT2D, PRC2, ASXL1/2). Episignature testing improves diagnostic yield in suggestive phenotypes with negative sequencing and can detect low-level postzygotic mosaicism in some epigenes.

Indexed context

Ciolfi A, et al.

chromatinopathyepisignaturemethylationreviewovergrowth

Markdown path

content/research/papers/2024-chromatinopathies-episignature-review.md

Findings

Review of ~154 epigenes now linked to Mendelian chromatinopathies, many with distinctive blood methylation episignatures. Signatures may overlap across functional complexes (KDM6A/KMT2D, PRC2, ASXL1/2). Episignature testing improves diagnostic yield in suggestive phenotypes with negative sequencing and can detect low-level postzygotic mosaicism in some epigenes.

Why it may matter for Levi

Frames the broader chromatinopathy axis into which DNMT3A, NSD1, EZH2, KMT2D, ATRX, and several other overgrowth / ID syndromes on Levi's differential all fall. Supports ordering a single episignature panel rather than gene-by-gene follow-up.

Paper text

Chromatinopathies: insight in clinical aspects and underlying epigenetic changes (review)

Ciolfi A, et al. — Human Genomics / PMC (2024). https://pmc.ncbi.nlm.nih.gov/articles/PMC11003913/

Findings summary

Review of the rapidly growing category of Mendelian chromatinopathies — neurodevelopmental syndromes caused by germline variants in genes that regulate chromatin structure and function ("epigenes"). Key points:

  • 154 epigenes have now been linked to chromatinopathies. Many of these show distinctive peripheral-blood DNA methylation patterns ("episignatures") that can be used both for diagnosis and for variant reclassification.
  • Episignatures can be disease-specific (one signature per gene, for example DNMT3A / TBRS) or shared across functional complexes. Known cross-overlap patterns exist between KDM6A and KMT2D (Kabuki 1/2), between polycomb repressive complex 2 members (EZH2, SUZ12, EED), and between polycomb deubiquitinase complex members (ASXL1, ASXL2).
  • Episignature testing improves the diagnostic yield meaningfully in patients with suggestive neurodevelopmental phenotypes and negative standard sequencing. In some cases, an episignature is the only positive molecular finding.
  • Episignature testing has been used to evaluate low-level postzygotic mosaicism for some epigenes (for example KMT2C and KMT2D).
  • The review positions DNA methylation analysis as a first-tier diagnostic in patients with clinical features of a Mendelian chromatinopathy, particularly when sequencing is uninformative.

Relevance to Levi

This review frames the broader category into which DNMT3A / TBRS, NSD1 / Sotos, EZH2 / Weaver, KMT2D / Kabuki, ATRX, and several other overgrowth / intellectual-disability syndromes on Levi's differential all fall. Three implications for Levi:

  1. A single episignature panel covers the chromatinopathy axis efficiently and can identify cases the existing short-read WGS pipeline cannot, including some postzygotic mosaic events in epigenetic-regulator genes.
  2. Overlap of episignatures across related complexes (KDM6A/KMT2D, PRC2, ASXL1/2) means a non-specific "chromatinopathy pattern" on EpiSign is itself informative and points to a cluster of candidate genes for targeted follow-up.
  3. Levi's residual "epigenetic overgrowth" differential (Sotos/Weaver/DNMT3A/NFIX/SETD2) should be framed explicitly as a methylation-panel-testable residual, not as something that will be resolved by further sequencing alone.

Provenance